The novel anti-diabetic agent canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has demonstrated efficacy in reducing cardiovascular mortality and heart failure-related hospitalizations in individuals with type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), although its precise mechanisms of action in the context of diabetic cardiomyopathy (DCM) remain still unclear (Packer, 2019). This evidence concerns the gene SLC5A2 and diabetic cardiomyopathy.